Ranking Profile - Kronos Worldwide Inc

Introduction

Kronos Worldwide Inc (Kronos) is a chemical company that manufactures and markets titanium dioxide (TiO2). The company's products include titanium chemicals, photocatalysts, iron salts in liquid and solid forms and TiO2 pigments for plastics, coatings, and paper. It offers products to plastic, paint, paper and decorative laminate manufacturers. TiO2 is also used in applications such as inks, cosmetics, textiles, beauty, health, and food. Kronos provides technical services for its products such as assistance, consultation, on-site training, and testing services. The company markets its products under the Kronos trademark through a network of distributors and agents across the world. The company has operational presence in Europe, North America, and Asia Pacific. Kronos is headquartered in Dallas, Texas, the United States.

Company info

Country (HQ): United States
Sector: Chemicals
Market Cap (US$ m): 942
Revenue (US$ m): 1,930 (2022)

Innovation ranking

321

Innovation score

Closest peers in the Chemicals sector

Innovation Ranking

Company
Headquarters
Sector

LG Chem Ltd

South Korea

Chemicals

Sumitomo Chemical Co Ltd

Japan

Chemicals

Kronos Worldwide Inc

United States

Chemicals

Shanghai Chlor-Alkali Chemical Co Ltd

China

Chemicals

PQ Group Holdings Inc

United States

Chemicals

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers